Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascendis Pharma AS

www.ascendispharma.com

Latest From Entera Health Inc.

Tackling Acute Gastroenteritis: RedHill Biopharma's Bekinda A Novel Approach?

A new long-acting ondansetron product that reduces nausea and vomiting during acute viral gastroenteritis, whatever the type of virus involved and for long periods of time, could change the way emergency physicians respond to gastroenteritis outbreaks, and is underpinning the specialty pharma business strategy of RedHill Biopharma.

Clinical Trials Business Strategies

Deals Shaping The Medical Industry, May 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.

Deals BioPharmaceutical

Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product

United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Ascendis Pharma AS
  • Senior Management
  • Jan Møller Mikkelsen, Pres. & CEO
    Scott T Smith, SVP, CFO
    Harald Rau, SVP, CSO
    Jonathan Leff, MD, CMO
  • Contact Info
  • Ascendis Pharma AS
    Phone: (45) 70 22 22 44
    Tuborg Blvd. 5
    Hellerup, DK-2900
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register